Veracyte VCYT 深 沪
已收盘 10-31 16:00:00 美东时间
36.08
+0.750
+2.12%
华盛通- 最 高36.38
- 今 开35.19
- 成交量 62.37万股
- 最 低 35.16
- 昨 收 35.33
- 总市值 28.38亿
- 52周最高 47.3162
- 市盈率 静 116.84
- 换手率 0.79%
- 52周最低 22.61
- 委 比 80.36%
- 总股本 7867.16万
- 历史最高 86.03
- 量 比 1.08
- 振 幅 3.45%
- 历史最低 4.21
- 每 手 1
- 风险率 5.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What to Expect from Kiniksa Pharmaceuticals's Earnings
Kiniksa Pharmaceuticals (NASDAQ:KNSA) is preparing to release its quarterly ear...
10-28 03:01
Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
10-27 20:01
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Freedom Capital Markets Initiates Coverage On Veracyte with Buy Rating, Announces Price Target of $45
Freedom Capital Markets analyst Keith Hinton initiates coverage on Veracyte (NASDAQ:VCYT) with a Buy rating and announces Price Target of $45.
10-17 20:23
Veracyte To Present First Prospective Data Predicting Hormone Therapy Benefit In Recurrent Prostate Cancer At ASTRO 2025
Findings are among nine Decipher-focused abstracts being presented at annual conferenceVeracyte, Inc. (NASDAQ:VCYT), a leading genomic diagnostics company, announced today that the first prospective validation data for a
09-24 21:08
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte advances its VAX-31 infant Phase 2 study to evaluate the optimized dose of the 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in infants. The optimized dose includes most serotypes at 4.4mcg and the balance at 3.3mcg, aiming to elicit stronger immune responses. The study, which now includes the optimized dose arm, will provide topline data by the end of the first half of 2027. VAX-31 i...
09-03 11:30
Veracyte Completes Enrollment Of 2,400 Patients In NIGHTINGALE Trial For Percepta Nasal Swab Lung Cancer Test
Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab
08-26 20:36
Veracyte Sees FY2025 Sales $496.000M-$504.000M vs $491.856M Est
2025 Financial OutlookThe company is raising full-year 2025 testing revenue guidance to $477 million to $483 million, or 14% to 15% year-over-year growth, from prior guidance of $470 million to $480 million. Adjusting
08-07 04:29
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
